Shionogi
OTC: SGIOF2 known investors
Find your way into Shionogi
Sign up to see every warm intro you have to Shionogi
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Shionogi team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Shionogi is a pharmaceutical company that discovers and develops medicines for challenging human diseases, including antibiotics and treatments for HIV, influenza, and COVID-19. It works to address global health challenges such as antimicrobial resistance, partnering with industry, government agencies, and early-stage biotechs.
Investors · 2
Related companies · 2
MedscapeMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
GlobaldataGlobalData provides an AI-powered intelligence platform that delivers research, market analysis, and predictive insights to enterprises across industries. The platform combines proprietary data, in-house subject matter experts, and AI tools to support critical business decisions.
Companies working in the same space as Shionogi.
Frequently asked questions
- What does Shionogi do?
- Shionogi is a pharmaceutical company that discovers and develops medicines for challenging human diseases, including antibiotics and treatments for HIV, influenza, and COVID-19. It works to address global health challenges such as antimicrobial resistance, partnering with industry, government agencies, and early-stage biotechs.
- Who are Shionogi's investors?
- Shionogi's investors include Advent Life Sciences, Solas BioVentures.



